自2023年开始，国家卫健委设立"癌症、心脑血管、呼吸和代谢性疾病防治研究国家科技重大专项"，旨 在依托国内主要研究力量和既有基础，解决"四大慢病"防治关键难题。今年5月，"江苏泰州方案"获 批，成为长三角地区唯一入选的地域方案，项目实施周期4年。项目负责人、南京医科大学附属泰州人 民医院院长陈明龙介绍，项目基于前期"星网计划"的探索，探索一体化慢病防控模式的构建与推广。 "星网计划"是泰州市重点推进的民生工程项目，核心理念是通过"人工智能+医疗"赋能基层，推动卫生 健康工作理念、服务方式从以治病为中心向以健康为中心转变。据南京医科大学附属泰州人民医院党委 书记朱莉介绍，医院着力构建"区域医疗中心—县域医院—中心医院—基层诊室"四级慢病管理网络。通 过运用物联网、人工智能、移动可穿戴设备等技术赋能基层医疗卫生机构，提供"防、筛、救、治、 康"全流程个体化防治服务，促使慢病患者回归村(社区)卫生室，乡村医生回归慢病防治主战场，医防 融合回归整合型管理模式。 本报讯(赵晓勇董龙江刘薇)近日，"四大慢病"国家科技重大专项——协同创新先行试验区(江苏泰州方 案)启动会在南京医科大学附属泰州人民医院举行。 ...

因此，上海中医药大学附属龙华医院凭借其在肿瘤领域的深厚临床积累，负责研究的整体设计与临床实 施；中国芳香疗法研究院作为国际疗法考试委员会(ITEC)认证的专业机构，为项目提供标准化的天然植 物精油原料与技术保障。这种优势互补的合作模式，旨在确保从干预材料到研究方法的全过程质量可 控，为产生高级别循证医学证据奠定坚实基础。 此次研究项目致力于探索一种高可及性、低负担的非药物解决方案，以应对肿瘤带来的疼痛、焦虑、恐 惧等心理社会挑战，相关研究成果有望为公共卫生领域的肿瘤心身管理提供新的选择方向。(记者陈植) 经济观察网2025年10月10日，上海中医药大学附属龙华医院与中国芳香疗法研究院宣布共同启动一项临 床观察研究项目，以探索药用植物来源精油对胰腺癌疼痛的辅助干预作用。 据悉，这个项目将基于中医"扶正治癌"理论，提出以药用植物来源精油为介质，重点评估此类精油通过 外用与嗅吸途径，在癌性疼痛管理过程的潜在价值，并系统探索其在肿瘤全周期管理中的应用前景。 癌性疼痛，特别是胰腺癌等难治性肿瘤引发的疼痛，严重影响患者的生活质量与治疗进程。当前医疗体 系虽已建立规范的疼痛药物治疗方案，但仍面临副作用、依赖性等挑战。 ...

Core Insights - Cell ferroptosis has been confirmed to be related to the development of various liver diseases [1] - A new study from Japan indicates that two volatile molecules produced during ferroptosis can be detected in the breath of patients [1] Group 1: Research Findings - Ferroptosis is a specific type of programmed cell death characterized by abnormal accumulation of iron ions and lipid peroxidation [1] - The main pathological process of ferroptosis involves irreversible damage to cell membrane structures due to lipid peroxidation, leading to loss of cell function [1] - Current detection methods for ferroptosis primarily rely on invasive tissue biopsies, which impose significant burdens on patients [1] Group 2: Methodology and Implications - Researchers from Kyoto University and other institutions utilized a newly developed oxidative volatile organic compound analysis technique to study volatile molecules released during ferroptosis [1] - The study identified two "iron-smelling molecules" that increase in concentration as ferroptosis progresses [1] - These molecules were found to be elevated in both the liver and breath of liver disease model mice, as well as in the breath of liver disease patients [1] Group 3: Future Applications - Based on the research findings, alternative methods to liver biopsy could be developed for health diagnostics and monitoring the progression of liver diseases [2] - The research results have been published in the journal "Redox Biology" [2]

Core Viewpoint - The recent exploratory clinical study on high-grade glioma demonstrates a significant advancement in radiotherapy precision, aiming to improve tumor targeting while protecting healthy brain tissue, thus offering new hope for patients [1][2][3] Group 1: Study Overview - The study titled "Modified Target Area Delineation Combined with Moderate Fractionated Radiotherapy for High-Grade Glioma" was published in the Journal of the American Medical Association Network Open [1] - The research team, consisting of experts from the Army Medical University, utilized advanced imaging techniques to enhance the accuracy of radiotherapy [3] Group 2: Clinical Significance - High-grade gliomas are known for their high incidence of neurological damage, with over half of patients experiencing cognitive impairments such as memory loss and confusion [1] - The annual incidence of brain gliomas in China is reported to be between 5 to 8 per 100,000, with a five-year mortality rate second only to pancreatic and lung cancers [1] Group 3: Treatment Methodology - Traditional treatment methods for high-grade gliomas involve maximum safe surgical resection followed by concurrent chemoradiotherapy, but these have not significantly improved patient outcomes [2] - The study introduces a more precise targeting method that aligns with the unique infiltration patterns of glioma cells, which tend to spread along established pathways rather than uniformly [2][3] Group 4: Research Findings - The prospective study included 154 patients, and the new method showed that patients receiving precise radiotherapy had longer survival rates without an increased risk of tumor recurrence [3] - International experts highlighted the importance of balancing treatment toxicity reduction with improved tumor control rates, emphasizing the innovative approach of this research [3]

Core Insights - The report published by The British Medical Journal highlights the significant impact of Chinese hospitals on global medical research and public health decision-making from 2005 to 2024, with over 12,000 articles cited in health policy and clinical guidelines across more than 75 countries, totaling nearly 35,000 citations [1][3] Group 1: Research Impact - The report emphasizes the increasing role of Chinese medical research in shaping international medical standards, enhancing healthcare supply, and improving patient treatment outcomes [3] - The top ten Chinese hospitals with the most cited articles include Sichuan University West China Hospital, Peking Union Medical College Hospital, Sun Yat-sen University First Affiliated Hospital, and Peking University First Hospital [3] Group 2: High-Quality Research Contributions - Chinese hospitals are progressively producing high-quality research that contributes significantly to global medical advancements, particularly in oncology, cardiology, and infectious diseases [5] - The "Beijing Plan" for haploidentical stem cell transplantation, developed by a Chinese academic, has provided hope for blood cancer patients globally [5] Group 3: Integration of Traditional and Modern Medicine - The integration of traditional Chinese medicine with modern technology is being showcased, with efforts to clarify the mechanisms of traditional remedies [6] - The development of innovative drugs, such as the anti-respiratory syncytial virus drug, demonstrates China's commitment to pediatric drug research [6] Group 4: Future Medical Innovations - The 2025 Service Trade Fair highlighted advancements in medical technology, including AI pediatricians and brain-machine interfaces, indicating a shift towards more sophisticated medical systems [8] - A groundbreaking clinical exploration of a brain-machine interface for treating spinal cord injuries was completed, showcasing China's innovative capabilities in medical research [8] Group 5: Global Collaboration and Health Goals - The Chinese government is committed to advancing medical technology research to address global health challenges and promote international collaboration [9]

BMJ集团发布中国医院研究影响力报告 21世纪经济报道 闫硕 2025-09-13 21:37 南方财经9月13日电，记者获悉，2025年9月12日-13日，首都国际医学大会于北京举行。国内外顶级专 家齐聚，围绕医学创新、全民健康覆盖、临床研究等核心议题，开展深层次研讨与交流。 在大会同期举办的中英医疗科创高峰论坛上，BMJ集团正式发布《2025中国医院研究影响力-全球卫生 政策和临床指南二十年引用报告》。该报告以2005-2024年为时间范围，将医院发表文章被全球卫生政 策和临床指南文件引用的情况作为核心衡量指标。 数据显示，被引用文章总数最多的十家医院在20年间的总被引用次数达34675次。这一成果充分表明， 中国医院在塑造国际医疗标准、提升医疗服务质量、改善全球患者治疗结局等推动医学科技进步的关键 领域，正发挥着愈发重要的作用。 （21世纪经济报道） 相关快讯 相关文章 南方财经9月13日电，记者获悉，2025年9月12日-13日，首都国际医学大会于北京举行。国内外顶级专 家齐聚，围绕医学创新、全民健康覆盖、临床研究等核心议题，开展深层次研讨与交流。 在大会同期举办的中英医疗科创高峰论坛上，BMJ集团正 ...

Core Viewpoint - The article discusses the evolving concept of diabetes remission, highlighting the increasing prevalence of diabetes globally and the need for new management strategies that focus on patient-centered approaches [5][6][19]. Summary by Sections Global Diabetes Prevalence - As of 2021, there are 537 million diabetes patients aged 20-79 worldwide, projected to exceed 783 million by 2045. The global medical expenditure related to diabetes reached $966 billion in 2021 [5]. Evolution of Diabetes Remission Concept - The traditional belief that type 2 diabetes is incurable has been challenged by new findings, particularly a 1992 study showing that 86.5% of patients achieved long-term normal blood sugar levels post metabolic surgery. The medical community reached a consensus in 2021 defining remission as maintaining HbA1c below 6.5% after stopping diabetes medication [8][10]. Controversies and Limitations of Current Standards - The current definition of diabetes remission faces challenges, including: 1. Over-reliance on blood sugar metrics, potentially overlooking other health risks [10]. 2. The requirement to stop medication may be inappropriate given the protective effects of new diabetes drugs [11]. 3. Psychological burdens on patients due to blood sugar fluctuations, leading to feelings of personal failure [12]. Four Scientific Strategies for Diabetes Remission - 1. **Lifestyle Interventions**: Strict dietary management and exercise can lead to remission, but maintaining these changes is challenging [13]. - 2. **Very Low-Calorie Diets**: Short-term diets (800-1200 kcal/day) can lead to significant weight loss and remission rates of 46% within a year, but require high adherence [14]. - 3. **New Medications**: GLP-1 receptor agonists and SGLT2 inhibitors not only control blood sugar but also provide cardiovascular protection, potentially redefining remission standards [15]. - 4. **Metabolic Surgery**: Effective for obese diabetes patients, with a remission rate of 72.3% within two years, but requires ongoing management to prevent weight regain [16]. Future Directions - The standards for diabetes remission need optimization, potentially moving towards: - Personalized definitions based on patient characteristics [17]. - Inclusion of protective medications in remission strategies [18]. - Dynamic assessments of remission as an ongoing process rather than a binary outcome [19].

Core Insights - A groundbreaking study published in the journal Nature reveals the biological mechanisms behind why individuals regain weight after losing it, highlighting the phenomenon of "inflammatory memory" in fat cells [5][7]. Group 1: Research Findings - The research led by the ETH Zurich team discovered that even after successful weight loss, human fat cells retain an epigenetic "memory" of their previous obese state, which contributes to weight regain [7]. - Using high-precision single-cell RNA sequencing (snRNA-seq), the study compared fat tissue samples from humans and mouse models, finding significant transcriptional changes in fat tissue post-weight loss [7]. - Notably, the "pro-inflammatory memory" in macrophages remains persistent, indicating that inflammatory signals continue to exist even when body weight normalizes [7]. Group 2: Implications for Weight Management - The study indicates that the longer an individual has been obese, the stronger the impact of this "fat memory," explaining why long-term obese individuals are more prone to weight regain after dieting [7]. - While weight loss can eliminate some senescent cells and reverse immune dysregulation, it does not fully eradicate the pro-inflammatory memory in macrophages, suggesting that future weight loss therapies may need to target this inflammatory memory mechanism for effective long-term weight management [7]. - This scientific breakthrough could shift the understanding of obesity treatment from a simple "weight loss" approach to a more complex "cellular memory reset" strategy, offering new hope for billions affected by obesity globally [7].

Core Insights - The article highlights a concerning trend in diabetes prevalence in China, indicating a significant increase in the number of patients and the urgent need for effective prevention and control strategies [9][15]. Group 1: Diabetes Prevalence and Trends - As of 2023, the total number of diabetes patients in China has reached 233 million, with a prevalence rate of 15.88%, marking a 163% increase from 88.48 million patients in 2005 [9][15]. - The age-standardized prevalence rate (ASR) of diabetes has risen from 7.53% in 2005 to 13.67% in 2023, with an annual growth rate of 3.36% [9][10]. - The years of life lost due to disability (YLDs) related to diabetes reached 32.49 million in 2023, reflecting a significant decline in overall health quality among the population [9][10]. Group 2: Regional Distribution and Characteristics - The eastern region of China has the highest number of diabetes patients at 78.47 million, followed by central and northern regions with 53.98 million and 36.06 million patients, respectively [11][12]. - The northern region has the highest ASR at 17.20%, with major cities like Beijing and Tianjin exceeding a 20% prevalence rate due to dietary habits [11][12]. - The southwestern region is experiencing the fastest growth in diabetes prevalence, increasing from 5.65% in 2005 to 11.77% in 2023, driven by changes in dietary patterns [12][13]. Group 3: Future Projections and Strategies - Projections indicate that if current trends continue, the ASR of diabetes could reach 16.15% by 2030, 21.52% by 2040, and potentially 29.10% by 2050, posing unprecedented challenges to the healthcare system [13][15]. - Implementing systematic obesity intervention strategies could significantly improve these projections, potentially keeping the ASR below 15% by 2050, a reduction of 49.10% from the natural trajectory [13][14]. - The article emphasizes the need for differentiated regional strategies in diabetes prevention, focusing on early screening and lifestyle interventions tailored to local conditions [14][16].

Core Viewpoint - The article highlights the alarming increase in diabetes prevalence in China, emphasizing the urgent need for effective prevention and control strategies to address this public health crisis [9][15][16]. Summary by Sections Diabetes Prevalence and Trends - As of 2023, the total number of diabetes patients in China has reached 233 million, with a prevalence rate of 15.88%, marking a 163% increase from 88.48 million patients in 2005 [9][15]. - The age-standardized prevalence rate (ASR) has risen from 7.53% in 2005 to 13.67% in 2023, with an annual growth rate of 3.36% [9][10]. - The years of life lost due to disability (YLDs) related to diabetes reached 32.49 million in 2023, reflecting a significant decline in overall health quality [9]. Regional Distribution and Characteristics - The eastern region has the highest number of diabetes patients at 78.47 million, followed by central and northern regions [11]. - The northern region has the highest ASR at 17.20%, with major cities like Beijing and Tianjin exceeding a 20% prevalence rate [12]. - The southwestern region shows the fastest growth in diabetes prevalence, increasing from 5.65% in 2005 to 11.77% in 2023, driven by dietary changes [12]. Future Projections and Challenges - Projections indicate that if current trends continue, the ASR could reach 16.15% by 2030, 21.52% by 2040, and potentially 29.10% by 2050, adding nearly 150 million new diabetes patients [13][15]. - The healthcare system will face unprecedented pressure due to the high costs associated with diabetes treatment and management [10][15]. Prevention and Control Strategies - The article advocates for a shift from treatment to early screening, lifestyle interventions, and strengthening primary healthcare [10][15]. - A differentiated regional strategy is necessary, focusing on complication management in high-prevalence areas and lifestyle interventions in rapidly growing regions [14][16]. - Implementing obesity intervention strategies could significantly reduce the projected diabetes prevalence by 2050, potentially keeping it below 15% [13][15].